Loading
A phase 2/3 trial of NP-G2-044 in ovarian cancer, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) is a phase 2/3 interventional study registered as NCT07109414 by Novita Pharmaceuticals, Inc., with 380 participants enrolled, started 2025-12-29 and due to reach its primary completion in 2028-10-25. Interventions recorded: NP-G2-044 and PLD.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/